Effective treatment of rat adjuvant-induced arthritis by celastrol

Autoimmunity Reviews

Volumn 11, Issue 12, 2012, Pages 856-862

  Cascao R ^a   Vidal, B ^a   Raquel, H ^a   Neves Costa, A ^a   Figueiredo, N ^a,b   Gupta, V ^c   Fonseca, J E ^a,d   Moita, L F ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b Gulbenkian Programme for Advanced Medical Education   (Portugal)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Caspase 1; Celastrol; Digoxin; IL 1 ; Th17 cells; Wistar AIA rat model

Indexed keywords

CELASTROL; DIGOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; TUMOR NECROSIS FACTOR;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CELL CULTURE; CELL INFILTRATION; CELL POLARITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; RAT; REVIEW; RHEUMATOID ARTHRITIS; TH17 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CELL DIFFERENTIATION; CELL LINE; DIGOXIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERLEUKIN-1BETA; JOINTS; RATS; RATS, WISTAR; TH17 CELLS; TRITERPENES;

EID: 84866558326     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.02.022     Document Type: Review

References (33)

1. Lindqvist E., Saxne T., Geborek P., Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002, 61:1055-1059.
2. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
3. Klarenbeek N.B., Guler-Yuksel M., van der Kooij S.M., Han K.H., Ronday H.K., Kerstens P.J., et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011, 70:1039-1046.
4. Cascao R., Polido-Pereira J., Canhao H., Rodrigues A.M., Navalho M., Raquel H., et al. Caspase-1 is active since the early phase of rheumatoid arthritis. Clin Exp Rheumatol 2012, 30(1):0144.
5. Kastbom A., Johansson M., Verma D., Soderkvist P., Rantapaa-Dahlqvist S. CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis. Ann Rheum Dis 2010, 69:723-726.
6. Fontalba A., Martinez-Taboada V., Gutierrez O., Pipaon C., Benito N., Balsa A., et al. Deficiency of the NF-kappaB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity. J Immunol 2007, 179:4867-4873.
7. Kastbom A., Verma D., Eriksson P., Skogh T., Wingren G., Soderkvist P. Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology (Oxford) 2008, 47:415-417.
8. Shoenfeld Y., Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
9. Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol 2009, 5:648-652.
10. Balofsky A., Agmon-Levin N., Shoenfeld Y. The new H1N1 and HPV vaccines and old fears. Curr Opin Rheumatol 2010, 22:431-436.
11. Chung Y., Chang S.H., Martinez G.J., Yang X.O., Nurieva R., Kang H.S., et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
12. Kryczek I., Wei S., Vatan L., Escara-Wilke J., Szeliga W., Keller E.T., et al. Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 2007, 179:1423-1426.
13. Cascao R., Moura R.A., Perpetuo I., Canhao H., Vieira-Sousa E., Mourao A.F., et al. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther 2010, 12:R196.
14. Lasiglie D., Traggiai E., Federici S., Alessio M., Buoncompagni A., Accogli A., et al. Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS One 2011, 6:e20014.
15. He D., Xu Q., Yan M., Zhang P., Zhou X., Zhang Z., et al. The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 2009, 9:343.
16. Lee J.H., Koo T.H., Yoon H., Jung H.S., Jin H.Z., Lee K., et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006, 72:1311-1321.
17. Allison A.C., Cacabelos R., Lombardi V.R., Alvarez X.A., Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:1341-1357.
18. Huh J.R., Leung M.W., Huang P., Ryan D.A., Krout M.R., Malapaka R.R., et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 2011, 472:486-490.
19. Idris A.I., Libouban H., Nyangoga H., Landao-Bassonga E., Chappard D., Ralston S.H. Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 2009, 8:2339-2347.
20. da Silva J.A., Fonseca J.E., Graca L., Moita L., Carmo-Fonseca M. Reinnervation of post-arthritic joints in the rat. Clin Exp Rheumatol 1996, 14:43-51.
21. Tsubaki T., Arita N., Kawakami T., Shiratsuchi T., Yamamoto H., Takubo N., et al. Characterization of histopathology and gene-expression profiles of synovitis in early rheumatoid arthritis using targeted biopsy specimens. Arthritis Res Ther 2005, 7:R825-R836.
22. Franchi L., Eigenbrod T., Munoz-Planillo R., Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009, 10:241-247.
23. Yang H., Chen D., Cui Q.C., Yuan X., Dou Q.P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006, 66:4758-4765.
24. Ngassapa O., Soejarto D.D., Pezzuto J.M., Farnsworth N.R. Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea. J Nat Prod 1994, 57:1-8.
25. Li H., Jia Y.F., Pan Y., Pan D.J., Li D., Zhang L.X. Effect of tripterine on collagen-induced arthritis in rats. Zhongguo Yao Li Xue Bao 1997, 18:270-273.
26. Pinna G.F., Fiorucci M., Reimund J.M., Taquet N., Arondel Y., Muller C.D. Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun 2004, 322:778-786.
27. Li H., Zhang Y.Y., Tan H.W., Jia Y.F., Li D. Therapeutic effect of tripterine on adjuvant arthritis in rats. J Ethnopharmacol 2008, 118:479-484.
28. Tao X., Younger J., Fan F.Z., Wang B., Lipsky P.E. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002, 46:1735-1743.
29. Cascao R., Rosario H.S., Souto-Carneiro M.M., Fonseca J.E. Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev 2010, 9:531-535.
30. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
31. Genovese M., Durez P., Richards H., Hugot S., Thangavelu K., Mpofu S. Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: results of a phase IIb study 2010, ACR, abstr #L9:2010.
32. Ferraccioli G., Zizzo G. The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. Discov Med 2011, 11:413-424.
33. Genovese M.C., Cohen S., Moreland L., Lium D., Robbins S., Newmark R., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004, 50:1412-1419.